- Home
- VRCA vs STRO Comparison
VRCA vs STRO Comparison
Compare VRCA & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- STRO
- Stock Information
- Founded
- VRCA 2013
- STRO 2003
- Country
- VRCA United States
- STRO United States
- Employees
- VRCA N/A
- STRO N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRCA Health Care
- STRO Health Care
- Exchange
- VRCA Nasdaq
- STRO Nasdaq
- Market Cap
- VRCA 58.7M
- STRO 69.1M
- IPO Year
- VRCA 2018
- STRO 2018
- Fundamental
- Price
- VRCA $4.75
- STRO $0.88
- Analyst Decision
- VRCA Hold
- STRO Hold
- Analyst Count
- VRCA 5
- STRO 7
- Target Price
- VRCA $60.00
- STRO $1.97
- AVG Volume (30 Days)
- VRCA 36.2K
- STRO 598.8K
- Earning Date
- VRCA 11-03-2025
- STRO 11-12-2025
- Dividend Yield
- VRCA N/A
- STRO N/A
- EPS Growth
- VRCA N/A
- STRO N/A
- EPS
- VRCA N/A
- STRO N/A
- Revenue
- VRCA $14,704,000.00
- STRO $104,473,000.00
- Revenue This Year
- VRCA $264.34
- STRO $65.42
- Revenue Next Year
- VRCA $33.95
- STRO N/A
- P/E Ratio
- VRCA N/A
- STRO N/A
- Revenue Growth
- VRCA 5.72
- STRO N/A
- 52 Week Low
- VRCA $3.82
- STRO $0.52
- 52 Week High
- VRCA $20.60
- STRO $4.80
- Technical
- Relative Strength Index (RSI)
- VRCA 31.51
- STRO 47.46
- Support Level
- VRCA $4.87
- STRO $0.90
- Resistance Level
- VRCA $5.20
- STRO $1.01
- Average True Range (ATR)
- VRCA 0.36
- STRO 0.09
- MACD
- VRCA -0.04
- STRO -0.00
- Stochastic Oscillator
- VRCA 0.57
- STRO 13.40
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.